What is the ROCE (Return on Capital Employed) of Theranexus this year?
The ROCE of Theranexus is -3.44 undefined this year.
Theranexus ROCE 2024
Theranexus ROCE
-3.44
Ticker
ALTHX.PA
ISIN
FR0013286259
WKN
A2H6LX
In 2024, Theranexus's return on capital employed (ROCE) was -3.44, a 214.96% increase from the -1.09 ROCE in the previous year.
Theranexus Aktienanalyse
What does Theranexus do?
Theranexus SA is a French biotechnology company founded in Lyon in 2013. The company specializes in the development of drugs for the treatment of neurodegenerative diseases. It is one of the few companies specialized in the synthesis of drug candidates through the combination of molecules. The idea to create Theranexus arose from the collaboration between Mathieu Charveriat and Franck Mouthon, two experienced researchers who both worked at the CNRS laboratory at the University of Lyon. Their goal was to synthesize a new class of molecules that are more effective in the treatment of neuropsychiatric disorders such as depression, anxiety, narcolepsy, and Alzheimer's. The company specializes in two main areas: the development of novel drugs and the identification of drug candidates through the modulation of molecules that influence neuronal communication. Theranexus closely collaborates with academic partners to develop a wide range of therapeutic options for neurodegenerative diseases. The company focuses on the development of drugs that work in a unique and seamless way. Theranexus SA has a unique business model in the field of drug development. The company utilizes its innovative technology platform to combine and rearticulate molecules that can influence neuronal communication. The company aims to expand its technology platform and extend its research to other disease areas. The company operates two main activities: the development of drug candidates for the treatment of neurodegenerative diseases and the identification of new drug candidates through the modulation of molecules that influence neuronal communication. The company has recently developed a cathepsin S platform that focuses on the discovery of drugs and drug candidates for the treatment of neurodegenerative diseases. Cathepsin S is an enzyme involved in the formation of amyloid deposits that can play a role in Alzheimer's disease and other neurodegenerative diseases. Theranexus has also developed a platform for the formation of nanoparticles to enable drugs to have a longer half-life and reduce dosage. The company utilizes the platform to stabilize therapeutic molecules by modifying their chemical properties in the body. Theranexus's current products include ANX-368, a drug candidate for the treatment of narcolepsy, and THN102, a combination drug for the treatment of Parkinson's and sleep disorders. The drug candidate TNX-102 is being developed as a potential medication for the treatment of neuropathic pain. Overall, Theranexus SA aims to develop effective and innovative drugs for the treatment of neurodegenerative diseases. The company is committed to expanding its technology platform and continuing its research in other disease areas. Theranexus ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Theranexus's Return on Capital Employed (ROCE)
Theranexus's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Theranexus's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Theranexus's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Theranexus’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Theranexus stock
How has the ROCE (Return on Capital Employed) of Theranexus developed compared to the previous year?
The ROCE of Theranexus has increased by 214.96% increased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Theranexus?
A high Return on Capital Employed (ROCE) indicates that Theranexus has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Theranexus?
A low ROCE (Return on Capital Employed) can indicate that Theranexus has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Theranexus impact the company?
An increase in the ROCE of Theranexus can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Theranexus affect the company?
A decrease in ROCE of Theranexus can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Theranexus?
Some factors that can affect Theranexus's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Theranexus so important for investors?
The ROCE of Theranexus is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Theranexus take to improve the ROCE?
To improve the ROCE, Theranexus can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Theranexus pay?
Over the past 12 months, Theranexus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Theranexus is expected to pay a dividend of 0 EUR.
What is the dividend yield of Theranexus?
The current dividend yield of Theranexus is .
When does Theranexus pay dividends?
Theranexus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Theranexus?
Theranexus paid dividends every year for the past 0 years.
What is the dividend of Theranexus?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Theranexus located?
Theranexus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Theranexus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Theranexus from 9/30/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.
When did Theranexus pay the last dividend?
The last dividend was paid out on 9/30/2024.
What was the dividend of Theranexus in the year 2023?
In the year 2023, Theranexus distributed 0 EUR as dividends.
In which currency does Theranexus pay out the dividend?
The dividends of Theranexus are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Theranexus
Our stock analysis for Theranexus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Theranexus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
